By Andrea Anderson

WASHINGTON, DC (GenomeWeb News) – The Cancer Genome Atlas (TCGA) plans to completely characterize 200 samples from each of 10 tumor types over the next two years and 20 tumor types within five years, attendees at the American Association for Cancer Research annual meeting heard here yesterday.

As in the pilot stage of the project, Phase II of TCGA will involve sequence, SNP, and copy number analyses for each cancer type, as well as studies of expression, methylation, and small RNA profiles.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.